Hepatitis B, Chronic
Conditions
Keywords
Hepatitis B, chronic, Peginterferon alfa-2a, Entecavir
Brief summary
Currently, peginterferon alfa-2a or oral nucleos(t)ides are approved for the treatment with HBeAg positive CHB, with the overall HBeAg seroconversion far from satisfactory. Therefore, efforts on the various combinations with the currently available drugs are needed to improve the overall response rates. The simultaneous combination therapy with oral nucleoside and peginterferon alfa-2a from large-scaled randomized trials did not show a superior response rate over peginterferon alfa-2a monotherapy. Recently, sequential monotherapy with lamivudine for the first 4 weeks, followed by weekly peginterferon alfa-2a has shown favorable HBeAg seroconversion rate over peginterferon alfa-2a monotherapy, based on the assumption that early viral suppression by lamivudine can restore the immune function to facilitate the later immunomodulatory response by peginterferon alfa-2a. With the recent introduction of entecavir, the more potent oral nucleoside with few drug resistance, sequential monotherapy with entecavir can potently suppress HBV DNA with 4 weeks of treatment, which may facilitate the response of peginterferon alfa-2a to achieve HBeAg seroconversion. Therefore, we aimed to conduct a placebo controlled randomized control trial to evaluate of adding entecavir early in the course of therapy can improve the treatment response.
Detailed description
Chronic hepatitis B (CHB) is prevalent in the world, with estimated chronic carriers of 350 millions worldwide. Currently, peginterferon alfa-2a or oral nucleos(t)ides are approved for the treatment with HBeAg positive CHB, with the overall HBeAg seroconversion far from satisfactory. Therefore, efforts on the various combinations with the currently available drugs are needed to improve the overall response rates. The simultaneous combination therapy with oral nucleoside and peginterferon alfa-2a from large-scaled randomized trials did not show a superior response rate over peginterferon alfa-2a monotherapy. Recently, sequential monotherapy with lamivudine for the first 4 weeks, followed by weekly peginterferon alfa-2a has shown favorable HBeAg seroconversion rate over peginterferon alfa-2a monotherapy, based on the assumption that early viral suppression by lamivudine can restore the immune function to facilitate the later immunomodulatory response by peginterferon alfa-2a. With the recent introduction of entecavir, the more potent oral nucleoside with few drug resistance, sequential monotherapy with entecavir can potently suppress HBV DNA with 4 weeks of treatment, which may facilitate the response of peginterferon alfa-2a to achieve HBeAg seroconversion. Therefore, we aimed to conduct a placebo controlled randomized control trial to evaluate of adding entecavir early in the course of therapy can improve the treatment response.
Interventions
DRUGEntecavir and peginterferon alfa-2a
Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
DRUGPlacebo and peginterferon
Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
Sponsors
National Science and Technology Council, Taiwan
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chronic hepatitis B (presence of HBsAg \> 6 months) with HBeAg persistence for more than 3 months * Age older than 18 years * HBV DNA \> 20,000 IU/mL for more than 2 occasions * Serum ALT levels between 2 to 10 folds the upper limit of normal (ULN) * A liver biopsy compatible with chronic hepatitis B
Exclusion criteria
* Anemia (hemoglobin \< 13 gram per deciliter for men and \< 12 gram per deciliter for women) * Neutropenia (neutrophil count \<1,500 per cubic milliliter) * Thrombocytopenia (platelet \<90,000 per cubic milliliter) * Co-infection with hepatitis B virus (HBV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) * Chronic alcohol abuse (daily consumption \> 20 gram per day) * Decompensated liver disease (Child-Pugh class B or C) * Serum creatinine level more than 1.5 times the upper limit of normal * Autoimmune liver disease * Neoplastic disease * An organ transplant * Immunosuppressive therapy * Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus Evidence of drug abuse * Unwilling to have contraception * Known allergic reaction to entecavir or peginterferon alfa-2a * Unwilling to sign inform consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBeAg seroconversion rate 6 months after the cessation of therapy | 76 weeks |
Countries
Taiwan
Contacts
Primary ContactChen-Hua Liu, MD
Backup ContactJia-Horng Kao, MD, PhD
Outcome results
None listed